| Digestive System Carcinoma altered in cohorts of …ALTERED_INderived200 of 1,030show all (up to 200) |
|---|
| ← altered in cohorts of | CD40 151 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNF4A 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCK1 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RIMS4 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SGK2 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRPC4AP 150 / 171 cases (88 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BLCAP 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BMP7 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BPI 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BPIFB3 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COX4I2 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EDN3 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EMILIN3 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM83D 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FOXS1 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GCNT7 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HM13 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MROH8 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYL9 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGT 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RBM39 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPN2 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC35C2 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC9A8 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPO11 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SUN5 149 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADIG 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C20orf173 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CNBD2 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPPIN-WFDC6 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ERGIC3 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM209B 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM210B 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAFB 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MMP24 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OSBPL2 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OSER1 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAE1 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RTF2 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERINC3 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNAI1 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TP53RK 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VAPB 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WFDC11 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WFDC13 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WFDC3 148 / 171 cases (87 %) · ssm · TCGA-READ | — | — | Rectal Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf158 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMK2N1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMTA1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAPZB 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCN6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDOST 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DHRS3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAJC11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | E2F2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECE1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF4G3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELOA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EMC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM43B 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO42 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HMGCL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPR 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HP1BP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR1D 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IFFO2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF21 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KDM1A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LACTBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LDLRAD2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC38 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LUZP1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MFAP2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10-NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MST1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBPF1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBPF3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NPHP4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OTUD3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAX7 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDIK1L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDPN 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PINK1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PITHD1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2C 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2E 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2F 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHG5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF12 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF14 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF18 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF20 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF25 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF26 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF27 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF33 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF9 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAP1GAP 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RCC2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF186 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC66A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TEX46 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBXN10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP48 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VWA5B1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF436 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APC 5,400 / 7,237 cases (75 %) · ssm · crc_msk_2026 · largest of 31 cohorts | — | — | Rectal Adenocarcinoma | 31 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KCNB1 343 / 461 cases (74 %) · ssm · TCGA-COAD · largest of 3 cohorts | — | — | Colon Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | RUSC1 277 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC12A5 338 / 461 cases (73 %) · ssm · TCGA-COAD · largest of 2 cohorts | — | — | Colon Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TSHZ2 338 / 461 cases (73 %) · ssm · TCGA-COAD · largest of 3 cohorts | — | — | Colon Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | ZMYND8 338 / 461 cases (73 %) · ssm · TCGA-COAD · largest of 3 cohorts | — | — | Colon Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA3 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM189B 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PKLR 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC50A1 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THBS3 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TP53 5,295 / 7,237 cases (73 %) · ssm · crc_msk_2026 · largest of 72 cohorts | — | — | Rectal Adenocarcinoma | 72 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RALGAPB 337 / 461 cases (73 %) · ssm · TCGA-COAD · largest of 2 cohorts | — | — | Colon Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM15 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLK2 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST2 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA1 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FDPS 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INSRR 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTX1 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCAMP3 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIM46 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB7B 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARFGEF2 336 / 461 cases (73 %) · ssm · TCGA-COAD · largest of 3 cohorts | — | — | Colon Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | NCOA6 336 / 461 cases (73 %) · ssm · TCGA-COAD | — | — | Colon Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF2 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST1 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPM3 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA4 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GBA 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HCN3 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDC4 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KRTCAP2 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LENEP 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC1 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YY1AP1 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNFX1 335 / 461 cases (73 %) · ssm · TCGA-COAD · largest of 3 cohorts | — | — | Colon Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | CEP250 334 / 461 cases (72 %) · ssm · TCGA-COAD · largest of 2 cohorts | — | — | Colon Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DDX27 334 / 461 cases (72 %) · ssm · TCGA-COAD · largest of 3 cohorts | — | — | Colon Adenocarcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNQ2 334 / 461 cases (72 %) · ssm · TCGA-COAD | — | — | Colon Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF335 334 / 461 cases (72 %) · ssm · TCGA-COAD | — | — | Colon Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CKS1B 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FLAD1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GON4L 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MSTO1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PBXIP1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PYGO2 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RIT1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RXFP4 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHC1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC27A3 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMG5 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SYT11 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNN 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIAA1755 333 / 461 cases (72 %) · ssm · TCGA-COAD · largest of 2 cohorts | — | — | Colon Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | IQGAP3 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LMNA 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MEX3A 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMVK 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNAS 332 / 461 cases (72 %) · ssm · TCGA-COAD · largest of 5 cohorts | — | — | Colon Adenocarcinoma | 5 | Observed | gdc | graph → |